Tag:
Agenus
Latest Headlines
Latest Headlines
Agenus trades adjuvant rights to GSK for $115M to bolster oncology profile
Immunotherapy developer Agenus, looking to further invest in its immuno-oncology pipeline, plans to temporarily cash out of a deal with GlaxoSmithKline to grab $115 million in exchange for royalties it once held on an adjuvant for GSK's malaria and shingles vaccines.
Agenus mortgages some vaccine royalties for $115M in R&D; cash
Agenus is trading away future royalties on a GlaxoSmithKline-partnered vaccine adjuvant in exchange for up to $115 million, planning to invest the proceeds in its growing pipeline of immuno-oncology treatments.
Agenus bags cancer antibodies in $44M deal
Lexington, MA-based Agenus has bagged the rights to some cancer-related antibodies from Italy's Diatheva s.r.l., agreeing to fork over up to $44 million in milestones for a successful development program.
UPDATED: Analyst: Genocea's genital herpes vaccine better positioned than Agenus' to enter market
Genocea Biosciences' GEN-003 vaccine is well-positioned to compete in the genital herpes treatment market. It's in a better position, in fact, than Agenus' HerpV, according to a GlobalData analyst.
Incyte, Agenus partner on immuno-oncology targets in $410M deal
Incyte is jumping aboard Agenus' antibody discovery platform, signing up to partner on new immuno-oncology drugs with $60 million in cash and promises of up to $350 million in milestones. And the deal news quickly drove up Agenus' shares by more than 30% in premarket trading.
Biotechs angling for T-cell response in race for next-gen herpes vaccine
When Australian biotech Admedus announced Phase I results for its herpes simplex virus vaccine last week, it was far from the first company to do so. A whole new generation of vaccinemakers are trying their hand in a race that's heating up.
Agenus brain cancer vaccine boosts survival in PhII trial
Patients with a lethal form of brain cancer lived nearly twice as long as expected after receiving Agenus' ($AGEN) Prophage vaccine in a Phase II study, according to the company.
Agenus spikes on positive data for its brain cancer vaccine
Agenus' vaccine for a deadly form of brain cancer helped extend patients' lives in a single-arm study, the company said, news that sent its shares up as much as 20% on hopes it can find a partner to help it into Phase III.
UPDATED: Agenus' genital herpes vax cuts viral load 75% in PhII
After hitting its primary endpoint in a Phase II study last fall, Agenus was already leading a Sanofi-NIH collaboration in efforts to develop the first genital herpes vaccine. Now, it's built on that lead with new Phase II results for its therapeutic candidate, HerpV, which achieved statistical significance in reducing viral load.
Merck turns to tiny Agenus in hunt for new immunotherapies
Merck is looking to Lexington, MA-based Agenus to give the pharma giant an edge in the race to develop new immuno-oncology drugs.